Functional activity of the mouse flavin-containing monooxygenase forms 1, 3, and 5

Journal of Biochemical and Molecular Toxicology

Volumn 21, Issue 4, 2007, Pages 206-215

  Zhang, Jun ^a   Cerny, Matt A ^a   Lawson, Matt ^a   Mosadeghi, Ruzbeh ^a   Cashman, John R ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

Author keywords

Expression and purification; mFMO1; mFMO3; mFMO5; Mouse flavin containing monooxygenase; pH profile; Substrate specificity; Thermal stability

Indexed keywords

DIMETHYLANILINE MONOOXYGENASE; ESONARIMOD; HYBRID PROTEIN; IMIDAZOLE DERIVATIVE; ISOENZYME; MALTOSE BINDING PROTEIN; PHENOTHIAZINE DERIVATIVE; TRIMETHYLAMINE; CARRIER PROTEIN; DIMETHYLANILINE MONOOXYGENASE (N-OXIDE FORMING); MALTOSE-BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OXYGENASE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME ISOLATION; ENZYME MECHANISM; ENZYME PURIFICATION; ENZYME STABILITY; ENZYME SUBSTRATE COMPLEX; ESCHERICHIA COLI; LIVER METABOLISM; MOLECULAR CLONING; MOUSE; NONHUMAN; PH; THERMOSTABILITY; XENOBIOTIC METABOLISM; AFFINITY CHROMATOGRAPHY; ANIMAL; ARTICLE; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; HEAT; ISOLATION AND PURIFICATION; KINETICS; LIVER; MALE; METABOLISM; STRUCTURE ACTIVITY RELATION;

ESCHERICHIA COLI;

ANIMALS; CARRIER PROTEINS; CHROMATOGRAPHY, AFFINITY; CLONING, MOLECULAR; ENZYME STABILITY; ESCHERICHIA COLI; HEAT; HYDROGEN-ION CONCENTRATION; ISOENZYMES; KINETICS; LIVER; MALE; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; NADP; OXYGENASES; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 36048983802     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20176     Document Type: Conference Paper

References (28)

1. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 2005;106(3):357-387.
2. Cashman JR, Zhang J. Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 2006;46:65-100.
3. Hines RN, Hopp KA, Franco J, Saeian K, Begun FP. Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Mol Pharmacol 2002;62(2):320-325.
4. Hernandez D, Janmohamed A, Chandan P, Phillips IR, Shephard EA. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 2004;14(2):117-130.
5. Janmohamed A, Hernandez D, Phillips IR, Shephard EA. Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases (FMOs). Biochem Pharmacol 2004;68(1):73-83.
6. Zhang J, Cashman JR. Quantitative analysis of FMO gene mRNA levels in human tissues. Drug Metab Dispos 2006;34(1):19-26.
7. Falls JG, Blake BL, Cao Y, Levi PE, Hodgson E. Gender differences in hepatic expression of flavin-containing monooxygenase isoforms (FMO1, FMO3, and FMO5) in mice. J Biochem Toxicol 1995;10(3):171-177.
8. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 2002;51(2):236-243.
9. Cherrington NJ, Cao Y, Cherrington JW, Rose RL, Hodgson E. Physiological factors affecting protein expression of flavin-containing monooxygenases 1, 3 and 5. Xenobiotica 1998;28(7):673-682.
10. Falls JG, Cherrington NJ, Clements KM, Philpot RM, Levi PE, Rose RL, Hodgson E. Molecular cloning, sequencing, and expression in Escherichia coli of mouse flavin-containing monooxygenase 3 (FMO3): comparison with the human isoform. Arch Biochem Biophys 1997;347(1):9-18.
11. Cherrington NJ, Falls JG, Rose RL, Clements KM, Philpot RM, Levi PE, Hodgson E. Molecular cloning, sequence, and expression of mouse flavin-containing monooxygenases 1 and 5 (FMO1 and FMO5). J Biochem Mol Toxicol 1998;12(4):205-212.
12. Karoly ED, Rose RL. Sequencing, expression, and characterization of cDNA expressed flavin-containing monooxygenase 2 from mouse. J Biochem Mol Toxicol 2001;15(6): 300-308.
13. Noguchi T, Onodera A, Tomisawa K, Yokomori S. A practical procedure for the synthesis of esonarimod, (R,S)-2-acetylthiomethyl-4-(4-methylphenyl)- 4-oxobutanoic acid, an antirheumatic agent (Part 1). Chem Pharm Bull (Tokyo) 2002;50:1407-1412.
14. Lomri N, Yang Z, Cashman JR. Expression in Escherichia coli of the flavin-containing monooxygenase D (form II) from adult human liver: determination of a distinct tertiary amine substrate specificity. Chem Res Toxicol 1993;6(4):425-429.
15. Nagata T, Williams DE, Ziegler DM. Substrate specificities of rabbit lung and porcine liver flavin-containing monooxygenases: differences due to substrate size. Chem Res Toxicol 1990;3(4):372-376.
16. Brunelle A, Bi YA, Lin J, Russell B, Luy L, Berkman C, Cashman J. Characterization of two human flavin-containing monooxygenase (form 3) enzymes expressed in Escherichia coli as maltose binding protein fusions. Drug Metab Dispos 1997;25(8):1001-1007.
17. Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, Cashman JR. Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies. Drug Metab Dispos 2003;31(7):854-860.
18. Ohmi N, Yoshida H, Endo H, Hasegawa M, Akimoto M, Higuchi S. S-oxidation of S-methyl-esonarimod by flavin-containing monooxygenases in human liver microsomes. Xenobiotica 2003;33(12):1221-1231.
19. Lomri N, Yang Z, Cashman JR, Regio- and stereoselective oxygenations by adult human liver flavin-containing monooxygenase 3. Comparison with forms 1 and 2. Chem Res Toxicol 1993;6(6):800-807.
20. Overby LH, Buckpitt AR, Lawton MP, Atta-Asafo-Adjei E, Schulze J, Philpot RM. Characterization of flavin-containing monooxygenase 5 (FMO5) cloned from human and guinea pig: evidence that the unique catalytic properties of FMO5 are not confined to the rabbit ortholog. Arch Biochem Biophys 1995;317(1):275-284.
21. Overby LH, Carver GC, Philpot RM. Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 1997;106(1):29-45.
22. Kim YM, Ziegler DM. Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase 1. Drug Metab Dispos 2000;28(8):1003-1006.
23. Ziegler DM. Flavin-containing monooxygenases: catalytic mechanism and substrate specificities. Drug Metab Rev 1988;19(1):1-32.
24. Ziegler DM. An overview of the mechanism, substrate specificities, and structure of FMOs. Drug Metab Rev 2002;34(3):503-511.
25. Schreuder HA, Prick PA, Wierenga RK, Vriend G, Wilson KS, Hol WG, Drenth J. Crystal structure of the p-hydroxybenzoate hydroxylase-substrate complex refined at 1.9 Å resolution. Analysis of the enzyme-substrate and enzyme-product complexes. J Mol Biol 1989;208(4):679-696.
26. Frederick KK, Palfey BA. Kinetics of proton-linked flavin conformational changes in p-hydroxybenzoate hydroxylase. Biochemistry 2005;44(40):13304-13314.
27. Ballou DP, Entsch B, Cole LJ. Dynamics involved in catalysis by single-component and two-component flavin-dependent aromatic hydroxylases. Biochem Bio Phys Res Commun 2005;338(1):590-598.
28. Lang DH, Rettie AE. In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol 2000;50(4):311-314.